GWS
TEVA icon

Glassman Wealth Services’s Teva Pharmaceuticals TEVA Stock Holding History

Glassman Wealth Services’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-707
Closed -$7.38K – 1635
2023
Q4 		$7.38K Buy
707
+1
+0.1% +$9 ﹤0.01% 957
2023
Q3 		$7.2K Buy
706
+275
+64% +$2.56K ﹤0.01% 956
2023
Q2 		$3.25K Sell
431
-61
-12% -$495 ﹤0.01% 1116
2023
Q1 		$4.35K Sell
492
-19
-4% -$188 ﹤0.01% 1039
2022
Q4 		$4.66K Buy
511
+56
+12% +$489 ﹤0.01% 1033
2022
Q3 		$4K Sell
455
-314
-41% -$2.78K ﹤0.01% 1083
2022
Q2 		$6K Buy
769
+185
+32% +$1.61K ﹤0.01% 967
2022
Q1 		$5K Sell
584
-143
-20% -$1.19K ﹤0.01% 1015
2021
Q4 		$6K Buy
727
+435
+149% +$3.93K ﹤0.01% 946
2021
Q3 		$3K Buy
292
+49
+20% +$459 ﹤0.01% 1101
2021
Q2 		$2K Sell
243
-11
-4% -$116 ﹤0.01% 1182
2021
Q1 		$3K Sell
254
-74
-23% -$849 ﹤0.01% 1023
2020
Q4 		$3K Buy
328
+143
+77% +$1.37K ﹤0.01% 1009
2020
Q3 		$2K Buy
185
+69
+59% +$730 ﹤0.01% 1037
2020
Q2 		$1K Sell
116
-4
-3% -$45 ﹤0.01% 1114
2020
Q1 		$1K Hold
120
– – ﹤0.01% 992
2019
Q4 		$1K Buy
120
+20
+20% +$179 ﹤0.01% 1044
2019
Q3 		$1K Hold
100
– – ﹤0.01% 925
2019
Q2 		$1K Sell
100
-6
-6% -$72 ﹤0.01% 937
2019
Q1 		$2K Buy
106
+6
+6% +$106 ﹤0.01% 724
2018
Q4 		$2K Hold
100
– – ﹤0.01% 577
2018
Q3 		$2K Hold
100
– – ﹤0.01% 619
2018
Q2 		$2K Hold
100
– – ﹤0.01% 586
2018
Q1 		$2K Hold
100
– – ﹤0.01% 558
2017
Q4 		$2K Hold
100
– – ﹤0.01% 516
2017
Q3 		$2K Hold
100
– – ﹤0.01% 425
2017
Q2 		$3K Sell
100
-200
-67% -$6.19K ﹤0.01% 400
2017
Q1 		$10K Hold
300
– – 0.01% 355
2016
Q4 		$11K Buy
300
+99
+49% +$3.95K 0.01% 359
2016
Q3 		$9K Sell
201
-99
-33% -$5.17K 0.01% 310
2016
Q2 		$15K Hold
300
– – 0.01% 268
2016
Q1 		$16K Hold
300
– – 0.01% 248
2015
Q4 		$20K Hold
300
– – 0.02% 228
2015
Q3 		$17K Hold
300
– – 0.02% 243
2015
Q2 		$18K Hold
300
– – 0.01% 238
2015
Q1 		$19K Hold
300
– – 0.02% 235
2014
Q4 		$17K Buy
+300
New +$16.7K 0.01% 276

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Glassman Wealth Services's TEVA Position: Q1 2024 in Review

Glassman Wealth Services sold out of Teva Pharmaceuticals (TEVA) in Q1 2024, closing a stake of 707 shares — an estimated $7.38K sold.

Glassman Wealth Services first reported a position in TEVA in Q4 2014 and held it in 37 quarters. The position peaked at $20K in Q4 2015. 481 funds tracked by Wall St. Rank hold TEVA as of Q1 2024.

  • Glassman Wealth Services reported no remaining Teva Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Glassman Wealth Services sold 707 Teva Pharmaceuticals shares in Q1 2024, an estimated $7.38K.
  • Glassman Wealth Services first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 37 quarters.
  • Glassman Wealth Services's Teva Pharmaceuticals position peaked at $20K in Q4 2015.
  • 481 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2024.

Based on Glassman Wealth Services's 13F filing for Q1 2024, filed 3 May 2024.